Thanks very much, BDZ.... I had not realized that "we met the primary endpoint" is all we're likely to get. I suppose that the better the results the more likely they are to give us an RRR%. On the other hand, Amarin doing so may have had something to do with the fact that it was the second Phase 3 they'd had to run for Vascepa due to the FDA's label restrictions after the first trial, and the company wanted to really rub it in this time.

So, back to that primary endpoint. Is that endpoint sufficiently ambitious in A's trial to assume that it being met is strong evidence of overall success?